Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
RecruitingNot a traditional drug phaseinterventionalRules rewrite

Not a traditional drug phase: SFR application for Rhumatoid Arthisis

Rheumatoid arthritis (RA) and spondyloarthritis (SpA), including psoriatic arthritis (PsA), are chronic painful diseases that impair quality of life. Disease-modifying antirheumatic drugs (DMARDs) are used to control disease activity, reduce functional disability, and improve prognosis.

Official registry: https://clinicaltrials.gov/study/NCT07460739 · Assistance Publique - Hôpitaux de Paris · enrollment listed as 144

What this phase means

This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are SFR application. The registry lists allocation as randomized. Rheumatoid arthritis (RA) and spondyloarthritis (SpA), including psoriatic arthritis (PsA), are chronic painful diseases that impair quality of life.

They plan to enroll about 144 people at Paris. Taking part typically means using or being fitted with a device plus check-ins.

Official title (unrewritten)

Efficacy of a Self-Management Smartphone App in Promoting Safety Skills of Patients With Inflammatory Arthritis Treated by Anti-Rheumatic Drugs

Interventions: SFR application

Primary outcome (registry wording): safety skills regarding the use of tDMARDS

Who it is for (from inclusion criteria)

  • Ages 18 Years to 75 Years
  • Age between 18 and 75 years
  • Undergoing a treatment change to a tDMARD (biologic or JAK inhibitor) available in the SFR application
  • No therapeutic education on tDMARDs in the past two years
  • Ability to use a smartphone application
  • Ability to use a website
  • Ability to complete a questionnaire
  • Covered by social security or entitled to social protection

Public study contact (from the registry)

Catherine BEAUVAIS, Medical Doctor

+33149282520

catherine.beauvais@aphp.fr

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

Related recruiting trials in this snapshot

FAQ about this NCT record

Is NCT07460739 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07460739?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07460739?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary